Status:
COMPLETED
Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation
Lead Sponsor:
The Netherlands Cancer Institute
Collaborating Sponsors:
Astellas Pharma Inc
Conditions:
Prostate Cancer
DNA
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
Rationale: Understanding the mechanisms of enzalutamide as an androgen receptor inhibitor in early prostate cancer could lead to improved patient selection for treatment. Objective: To study the effe...
Detailed Description
Rationale: Understanding the mechanisms of enzalutamide as an androgen receptor inhibitor in early prostate cancer could lead to improved patient selection for treatment. Objective: To study the effe...
Eligibility Criteria
Inclusion
- Men over 18 years of age.
- clinically non-metastasized prostate cancer, tumor that can be imaged (TRUS or MRI) in order to allow for accurate preoperative biopsies.
- Gleason score 7-10
- written informed consent
- WHO performance 0-1
Exclusion
- A history of seizures.
- Clinically nodal metastases.
- Prostatitis or urinary tract infection.
- Androgen ablative therapy within 6 weeks of inclusion (including 5 alpha-reductase inhibitors).
- Tumor of the prostate that can not be visualized by TRUS or MRI.
Key Trial Info
Start Date :
August 28 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03297385
Start Date
August 28 2014
End Date
April 1 2017
Last Update
September 29 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.